SEC Filing Summary
Registrant identity warning: The supplied filing is Inotek Pharmaceuticals Corporation’s Form 10-Q, not a Rocket Pharmaceuticals, Inc. filing. It covers the quarter ended September 30, 2015, and was signed November 12, 2015. Confirm the issuer and filing before relying on this summary.
Business context and reporting period
Inotek was a clinical-stage biopharmaceutical company developing eye-disease therapies, principally trabodenoson for glaucoma, as monotherapy and in a fixed-dose combination with latanoprost. It had no approved products and no product-sale revenue. The company reported results for the three and nine months ended September 30, 2015, with comparisons to the same 2014 periods.
Financial performance and position
| Metric | Three months ended September 30, 2015 | Nine months ended September 30, 2015 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $3.612 million | $6.635 million |
| General and administrative expense | $1.825 million | $5.533 million |
| Operating loss | $5.437 million | $12.168 million |
| Net loss | $55.961 million | $59.810 million |
| Net loss per share, basic and diluted | $2.48 | $3.85 |
| Cash used in operating activities | Not separately presented for the quarter | $10.377 million |
At September 30, 2015, cash and cash equivalents were $89.248 million and short-term investments were $29.117 million, totaling $118.365 million. Current assets were $119.224 million; current liabilities were $3.243 million. Total liabilities were $3.649 million. The company had no notes payable or convertible notes outstanding at quarter-end. Revenue-based margins are not meaningful because the company had no product revenue.
Nine-month investing cash use was $29.435 million, mainly purchases of short-term investments and property and equipment. Financing activities provided $125.442 million, principally from the IPO and August follow-on stock offering, partly offset by debt repayment. Cash increased by $85.630 million from the beginning of 2015.
Changes versus prior comparable periods
- Third-quarter R&D expense rose $2.369 million from 2014, mainly from drug-product preparation for Phase 3 and increased staffing. Third-quarter G&A expense rose $0.982 million, primarily due to staffing, insurance and recruiting.
- Third-quarter net loss increased from $2.388 million in 2014 to $55.961 million in 2015. The main unusual driver was a $46.649 million noncash loss from remeasuring the embedded derivative in the 2020 Convertible Notes before their conversion; the quarter also included a $3.716 million debt-extinguishment loss.
- For the first nine months, net loss increased from $7.383 million in 2014 to $59.810 million in 2015. The 2015 period included a $42.793 million loss on the 2020 Notes derivative, partly offset by a $0.480 million gain on the Bridge Notes redemption-rights derivative, and $4.399 million of total debt-extinguishment losses.
- The company raised approximately $36.5 million net from IPO equity, $18.9 million net from the concurrent notes offering, and $74.0 million net from its August follow-on offering. All $21 million principal amount of the 2020 Convertible Notes converted into common stock in July and August, with additional shares issued for the interest make-whole payment. Outstanding preferred stock also converted to common stock in connection with the IPO.
Outlook, risks and other notable items
- Management estimated available cash and investments would fund operations for more than 12 months. It expected continued losses, higher operating expenses and a need for additional financing; no specific revenue or earnings guidance was provided.
- The first trabodenoson monotherapy Phase 3 trial began dosing in October 2015, after quarter-end. Management expected clinical trials for the fixed-dose combination to begin in 2016. The company had reached agreement with the FDA on the initial Phase 3 trial design and overall regulatory path.
- Key risks include clinical-trial failure or delay, safety and efficacy uncertainty, regulatory approval, formulation and manufacturing of the combination product, dependence on third-party contractors and manufacturers, intellectual-property protection, competition, reimbursement and the need to raise additional capital.
- The company reported no legal proceedings and no off-balance-sheet arrangements. It disclosed $2.145 million of future headquarters lease payments. Management concluded disclosure controls were effective at a reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the filing belongs to the intended issuer: the document identifies Inotek Pharmaceuticals Corporation, not Rocket Pharmaceuticals, Inc.
- Review the underlying financial statements and notes for the noncash derivative remeasurement and debt-extinguishment accounting that drove the reported net loss.
- Verify the timing, design, enrollment and subsequent results of the trabodenoson Phase 3 program, and the planned 2016 fixed-dose-combination program.
- Assess the assumptions behind management’s estimate of more than 12 months of funding and the likelihood, terms and dilution effects of future financing.
- Check subsequent disclosures for changes in cash runway, clinical or regulatory status, manufacturing readiness, and potential share dilution.